Registro de resultados prospectivos de fibrose pulmonar idiopática e doença pulmonar intersticial (IPF/ILD-PRO)
Registro de resultados prospectivos de fibrose pulmonar idiopática (IPF-PRO) e doença pulmonar intersticial fibrosante crônica com fenótipo progressivo (IPF-PRO/ILD-PRO)
The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the registry expanded to include recruitment of participants with other chronic fibrosing interstitial lung diseases (ILDs) with progressive phenotype also referred to as progressive fibrosing interstitial lung diseases in the Chronic Fibrosis Interstitial Lung Disease with Progressive Phenotype (ILD-PRO) Registry. When the third phase of the registry begins, the IPF-PRO registry will enroll additional patients with idiopathic pulmonary fibrosis. This IPF-PRO registry is a prospective registry that will collect information regarding the natural history, health care interactions, participant reported questionnaire data to assess quality of life, and the methods of treatment of participants with a diagnosis of idiopathic pulmonary fibrosis (IPF) or of another chronic fibrosing interstitial lung disease (ILD) with progressive phenotype established at the enrolling centers. In addition, blood samples and chest image studies will be collected and banked for future research projects.
Visão geral do estudo
Status
Status
Condições
Condições
Descrição detalhada
This registry originally enrolled a total of 1002 participants newly diagnosed with IPF and continues to enroll patients with other chronic fibrosing ILDs with newly identified progressive phenotype to reach an enrollment of 1000 patients. Participants will be enrolled in three phases, (IPF-PRO and ILD-PRO) over a span of 8 years at approximately 50 sites experienced in the diagnosis and treatment of ILD in the United States. Enrollment for the original IPF cohort started in 2014 and ended in October 2018, with 1002 total participants enrolled. In the third phase of the registry new enrollment for patients with IPF will restart in 2023-2024 with the plan to enroll up to 1000 new IPF patients, for a total IPF enrollment of 2000. Enrollment for other chronic fibrosing ILDs with newly identified progressive phenotype cohort was initiated in February 2019 and will end when enrollment reaches 1000 participants with the potential of enrolling another 1000 participants with other chronic fibrosing ILDs with newly identified without a progressive phenotype. Data and samples will be collected from participants for approximately 5 years for the IPF cohort. For the chronic fibrosing ILD with progressive phenotype cohort, data and samples will be collected for a minimum of 3 years, up to approximately 5 years. Participant management and treatment decisions will be determined by participants and their health care professionals.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Rosalia Blanco
- Número de telefone: 919-660-0890
- E-mail: rosalia.blanco@duke.edu
Locais de estudo
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35294
- Recrutamento
- University of Alabama - Birmingham
-
Investigador principal:
- Tejaswini Kulkarni, MD
-
Contato:
- Arnissa Hopson
- Número de telefone: 205-934-1657
- E-mail: agoggins@uabmc.edu
-
-
Arizona
-
Tucson, Arizona, Estados Unidos, 85721
- Recrutamento
- University of Arizona
-
Investigador principal:
- Sally A Suliman, MD
-
Contato:
- Daniel Castaneda-Beltran
- Número de telefone: 602-827-2347
- E-mail: dcastanedabeltra@arizona.edu
-
-
California
-
Los Angeles, California, Estados Unidos, 90033
- Recrutamento
- University of Southern California
-
Contato:
- Lynn Fukusima
- E-mail: Lynn.Fukushima@med.usc.edu
-
Investigador principal:
- Toby Maher, MD
-
Los Angeles, California, Estados Unidos, 90024
- Recrutamento
- University of California - Los Angeles
-
Investigador principal:
- John Belperio, MD
-
Contato:
- Stephanie Roblero
- Número de telefone: 310-627-2319
- E-mail: sroblero@mednet.ucla.edu
-
Stanford, California, Estados Unidos, 94305
- Recrutamento
- Stanford University
-
Investigador principal:
- Rishi Raj, MD
-
Contato:
- Summer Zhu
- Número de telefone: 650-724-5424
- E-mail: szhuye@stanford.edu
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- Recrutamento
- University of Colorado
-
Investigador principal:
- Joyce Lee, MD
-
Contato:
- Olivia Brohl
- Número de telefone: 303-724-0641
- E-mail: Olivia.brohl@cuanschutz.edu
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06520
- Recrutamento
- Yale University
-
Investigador principal:
- Mridu Gulati, MD
-
Contato:
- Maksym Minasyan
- Número de telefone: 203-785-4177
- E-mail: maksym.minasyan@yale.edu
-
-
Florida
-
Gainesville, Florida, Estados Unidos, 32610-3175
- Recrutamento
- University of Florida
-
Contato:
- Lisbetty Lugo
- E-mail: lisbetty.lugo@medicine.ufl.edu
-
Investigador principal:
- Diana Gomez Manjarres, MD
-
Tampa, Florida, Estados Unidos, 33606
- Recrutamento
- University of South Florida
-
Investigador principal:
- Jose D Herazo-Maya, MD
-
Contato:
- Natasha Brown
- E-mail: nbrown@tgh.org
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Recrutamento
- Emory University
-
Contato:
- Tracy Halabi
- Número de telefone: 404-712-7458
- E-mail: tracy.halaby@emory.edu
-
Investigador principal:
- Srihari Veeraraghavan, MD
-
Austell, Georgia, Estados Unidos, 30106
- Recrutamento
- Piedmont Healthcare
-
Investigador principal:
- Amy Case, MD
-
Contato:
- Munachi (Muna) Iwotor
- Número de telefone: 404-291-9062
- E-mail: munachi.iwotor@piedmont.org
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60637
- Recrutamento
- University of Chicago
-
Investigador principal:
- Mary Strek, MD
-
Contato:
- Vanita Patel
- E-mail: vpatel4@bsd.uchicago.edu
-
Evanston, Illinois, Estados Unidos, 60611
- Recrutamento
- Northwestern University
-
Contato:
- Phillip Cooper
- Número de telefone: 312-503-0406
- E-mail: p-cooper@northwestern.edu
-
Investigador principal:
- Bradford Bemiss, MD
-
Maywood, Illinois, Estados Unidos, 60153
- Recrutamento
- Loyola University Health System
-
Investigador principal:
- Daniel Dilling, MD
-
Contato:
- Sloan White
- E-mail: swhite29@luc.edu
-
-
Kansas
-
Kansas City, Kansas, Estados Unidos, 66160
- Rescindido
- University of Kansas
-
-
Kentucky
-
Lexington, Kentucky, Estados Unidos, 40536
- Recrutamento
- University of Kentucky
-
Investigador principal:
- Girish Nair, MD
-
Contato:
- Kai Su
- Número de telefone: 859-257-4501
- E-mail: kai.su@uky.edu
-
-
Louisiana
-
New Orleans, Louisiana, Estados Unidos, 70112
- Recrutamento
- Tulane University
-
Investigador principal:
- Joe Lasky, MD
-
Contato:
- Sandy Ditta
- Número de telefone: 504-988-4040
- E-mail: sditta@tulane.edu
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
- Ativo, não recrutando
- University of Michigan
-
Detroit, Michigan, Estados Unidos, 48202
- Recrutamento
- Henry Ford Health
-
Contato:
- Deepti Naidu
- Número de telefone: 313-916-8732
- E-mail: dnaidu1@HFHS.ORG
-
Investigador principal:
- Asif Abdul Hameed, MD
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55455
- Recrutamento
- University of Minnesota
-
Contato:
- Mandi DeGrote
- Número de telefone: 612-626-7609
- E-mail: carl1032@umn.edu
-
Investigador principal:
- Hyum Kim, MD
-
-
Mississippi
-
Jackson, Mississippi, Estados Unidos, 39216
- Recrutamento
- University of Mississippi Medical Center
-
Investigador principal:
- Kimberly Dobbs, MD
-
Contato:
- Leadeashia Brackett
- Número de telefone: 601-496-7814
- E-mail: lbrackett@umc.edu
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110
- Recrutamento
- Washington University
-
Investigador principal:
- Tonya Russell, MD
-
Contato:
- Mona Noroozi
- Número de telefone: 314-362-3705
- E-mail: mnoroozi@wustl.edu
-
-
New York
-
New York, New York, Estados Unidos, 10065
- Recrutamento
- Weill Medical College of Cornell University
-
Investigador principal:
- Kerri Aronson, MD
-
Contato:
- Alicia Morris
- Número de telefone: 646-692-2741
- E-mail: ajm2017@med.cornell.edu
-
New York, New York, Estados Unidos, 10016
- Ativo, não recrutando
- NYU Medical Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27514
- Recrutamento
- UNC Chapel Hill
-
Investigador principal:
- Jason Lobo, MD
-
Contato:
- Jackson Pettee
- E-mail: Jackson_pettee@med.unc.edu
-
Durham, North Carolina, Estados Unidos, 27705
- Recrutamento
- Duke University
-
Investigador principal:
- Lake Morrison, MD
-
Contato:
- Lauren Gray
- Número de telefone: 919-684-7317
- E-mail: lauren.gray@duke.edu
-
Greensboro, North Carolina, Estados Unidos, 27403
- Recrutamento
- Pulmonix LLC
-
Investigador principal:
- Murali Ramaswamy, MD
-
Contato:
- Mei Zheng
- Número de telefone: 336-522-8870
- E-mail: mei.zheng@pulmonix.com
-
Wilmington, North Carolina, Estados Unidos, 28401
- Rescindido
- PMG Research
-
Winston-Salem, North Carolina, Estados Unidos, 27157
- Recrutamento
- Wake Forest Baptist Health
-
Contato:
- Bob Hmieleski
- Número de telefone: 336-713-8550
- E-mail: bhmieles@wakehealth.edu
-
Investigador principal:
- Andrew Namen, MD
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45267
- Ativo, não recrutando
- University of Cincinnati Medical Center
-
Cleveland, Ohio, Estados Unidos, 44195
- Recrutamento
- Cleveland Clinic
-
Investigador principal:
- Brian Southern, MD
-
Contato:
- Ron Wehrmann
- Número de telefone: 2164450574
- E-mail: wehrmar@ccf.org
-
Columbus, Ohio, Estados Unidos, 43210
- Recrutamento
- The Ohio State University
-
Contato:
- Benjamin Hood
- E-mail: benjamin.hood2@osumc.edu
-
Investigador principal:
- John Odackal
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- Recrutamento
- University of Oklahoma
-
Investigador principal:
- Jad Kebbe, MD
-
Contato:
- Maria Mason
- Número de telefone: 405-271-6173
- E-mail: maria-l-mason@ouhsc.edu
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97220
- Recrutamento
- Oregon Clinic
-
Investigador principal:
- David Hotchkin, MD
-
Contato:
- Meg Day
- Número de telefone: 503-963-3182
- E-mail: mday@orclinic.com
-
-
Pennsylvania
-
Hershey, Pennsylvania, Estados Unidos, 17033
- Recrutamento
- Penn State College of Medicine - Hershey
-
Investigador principal:
- Rebecca Bascom, MD
-
Contato:
- Tim Sheehan
- Número de telefone: 717-531-2925
- E-mail: tsheehan@pennstatehealth.psu.edu
-
Philadelphia, Pennsylvania, Estados Unidos, 19140
- Recrutamento
- Temple University
-
Investigador principal:
- Rachel Criner, MD
-
Contato:
- Luis Cardenas-Osorio
- Número de telefone: 215-707-3311
- E-mail: Luis.Cardenas-Osorio@tuhs.temple.edu
-
Philadelphia, Pennsylvania, Estados Unidos, 19144
- Recrutamento
- Thomas Jefferson University
-
Investigador principal:
- Ross Summer, MD
-
Contato:
- Ramya Talluri, BSN, RN
- E-mail: RamyaPriya.Talluri@jefferson.edu
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 29425
- Recrutamento
- Medical University of South Carolina
-
Investigador principal:
- Timothy Whelan, MD
-
Contato:
- Audra Wiser
- E-mail: wisera@musc.edu
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37232
- Recrutamento
- Vanderbilt University
-
Contato:
- James Del Greco
- Número de telefone: 615-343-7068
- E-mail: james.del.greco@vumc.org
-
Investigador principal:
- Justin Hewlett, MD
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75235
- Recrutamento
- University of Texas Southwestern
-
Investigador principal:
- John Fitzgerald, MD
-
Contato:
- Meagan Galvan
- Número de telefone: 214-645-6489
- E-mail: Maegan.Galvan@UTSouthwestern.edu
-
Dallas, Texas, Estados Unidos, 75246
- Recrutamento
- Baylor University Medical Center at Dallas
-
Investigador principal:
- Yolanda Mageto, MD
-
Contato:
- Mary Alayo
- Número de telefone: 214-820-6276
- E-mail: Mary.Alayo@BSWHealth.org
-
Houston, Texas, Estados Unidos, 77030
- Recrutamento
- Baylor College of Medicine
-
Investigador principal:
- Ivan Rosas, MD
-
Contato:
- Maria C Perea
- E-mail: Maria.Perea@bcm.edu
-
Houston, Texas, Estados Unidos, 77030
- Recrutamento
- Houston Methodist Lung Center
-
Investigador principal:
- Zeenat Safdar, MD
-
Contato:
- Laura Valecillos Loukidis
- Número de telefone: 346-238-4637
- E-mail: lvvalecillosloukidis@houstonmethodist.org
-
Houston, Texas, Estados Unidos, 77030
- Recrutamento
- The University of Texas Health Science Center At Houston
-
Investigador principal:
- Rodeo Abrencillo, MD
-
Contato:
- Beverly Rios
- Número de telefone: 713-486-6152
- E-mail: Beverly.Rios@uth.tmc.edu
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84108
- Recrutamento
- University of Utah
-
Contato:
- Adeline Langer
- Número de telefone: 801-581-5811
- E-mail: adeline.langer@hsc.utah.edu
-
Investigador principal:
- Mary Beth Langer, MD
-
Salt Lake City, Utah, Estados Unidos, 84111
- Recrutamento
- Intermountain Health
-
Contato:
- Aisha Skowyra
- Número de telefone: 801-507-2439
- E-mail: Aisha.fairclough@imail.org
-
Investigador principal:
- Erin Blackstock, MD
-
-
Vermont
-
Colchester, Vermont, Estados Unidos, 05446
- Ativo, não recrutando
- University of Vermont Lung Center
-
-
Virginia
-
Charlottesville, Virginia, Estados Unidos, 22908
- Ativo, não recrutando
- University from Virginia
-
Falls Church, Virginia, Estados Unidos, 22042-3307
- Recrutamento
- Inova Health Care Services
-
Contato:
- Taruni Maganti
- Número de telefone: 703-776-3230
- E-mail: Taruni.Maganti@inova.org
-
Investigador principal:
- Jared Wilkinson, MD
-
-
Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Ativo, não recrutando
- The Medical College of Wisconsin
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Subjects with a new diagnosis of IPF or a non- IPF chronic fibrosing ILD established at the time of enrollment in the registry are eligible for participation in the IPF-PRO/ILD-PRO registry if the participant meets the selection criteria.
Descrição
Inclusion Criteria:
-
Willing and able to provide informed consent
-
Established a new diagnosis (within 12 months) of IPF by the enrolling center.
-
Age 21 years or older, or
-
Diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype during the last 24 months by the enrolling center that meets the following criteria:
-
Chronic fibrosing ILD as defined by reticular abnormality with traction bronchiectasis with or without honeycombing confirmed by chest HRCT scan and/or lung biopsy.
-
Progressive phenotype as defined by fulfilling at least one of the criteria below of fibrotic changes (progression set point) within the last 24 months regardless of treatment considered appropriate in individual ILDs (8):
- decline in FVC % predicted (% pred) based on ≥10% relative decline
- decline in FVC % pred based on ≥5 - <10% relative decline in FVC combined with worsening of respiratory symptoms as assessed by the site investigator
- decline in FVC % pred based on ≥5 - <10% relative decline in FVC combined with increasing extent of fibrotic changes on chest imaging (HRCT scan) as assessed by the site investigator
- decline in DLCO % pred based on≥ 10% relative decline
- worsening of respiratory symptoms as well as increasing extent of fibrotic changes on chest imaging (HRCT scan) as assessed by the site investigator independent of FVC change.
-
The relative decline for FVC % predicted is calculated using the formula:
Relative Decline= (FVC % Pred (Reference)-FVC % Pred (Screening))/(FVC % Pred (Reference))×100%, where FVC % Pred (Reference) is the greatest measurement of FVC % predicted in the 24 months prior to screening and FVC % Pred (Screening) is the measurement of FVC % predicted at screening.
The relative decline for DLCO % predicted is calculated using the formula:
Relative Decline= (DLCO % Pred (Reference)-DLCO % Pred (Screening))/(DLCO % Pred (Reference))×100%, Where DLCO % Pred (Reference) is the greatest measurement of DLCO % Pred in the 24 months prior to screening and DLCO % Pred (Screening) is the measurement of DLCO % Pred at screening
Exclusion Criteria:
- Malignancy, treated or untreated, other than skin or early -stage prostate cancer, within the past 5 years
- Currently listed for lung transplantation at the time of enrollment
- Currently enrolled in an interventional clinical trial at the time of enrollment in this registry
- For the additional IPF cohort of 1000 individuals, previous enrollment in this registry.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
Número de grupos/coortes
Coortes e Intervenções
Grupo / CoorteGrupo / Coorte |
|---|
|
Subjects with a new IPF diagnosis
Subjects with a new diagnosis of IPF established at the time of enrollment in the registry |
|
Subjects with a non-IPF ILD diagnosis
Subjects with a diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype |
|
New Subjects with a new IPF diagnosis
Subjects with a new diagnosis of IPF established at the time of enrollment in the registry not previously enrolled in the registry. |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Data on natural history of IPF & non-IPF chronic fibrosing ILD
Prazo: End of Study (3 years after last patient will be enrolled)
|
Characterize and describe the natural history of patients with a recent confirmed diagnosis of IPF, with emphasis on demographics, co-morbidities, medications, and risks for disease progression or death. |
End of Study (3 years after last patient will be enrolled)
|
|
Data on current practice patterns for diagnosis of IPF & non-IPF chronic fibrosing ILD
Prazo: End of Study (3 years after last patient will be enrolled)
|
Understand the current practice patterns for diagnosis of IPF & non-IPF chronic fibrosing ILD |
End of Study (3 years after last patient will be enrolled)
|
|
Data on impact of IPF & non- IPF chronic fibrosing ILD on patient quality of life.
Prazo: End of Study (3 years after last patient will be enrolled)
|
Describe the impact of IPF & non- IPF chronic fibrosing ILD on patient quality-of-life (QOL). |
End of Study (3 years after last patient will be enrolled)
|
|
Blood samples for future research.
Prazo: End of Study (3 years after last patient will be enrolled)
|
Collect longitudinal bio-samples for future research on disease presentation, progression, and subject response to clinical interventions. |
End of Study (3 years after last patient will be enrolled)
|
|
HRCT images for future research (for non-IPF chronic fibrosing ILD, and new IPF patients cohort)
Prazo: End of Study (3 years after last patient will be enrolled)
|
Collect longitudinal HRCT images for future research |
End of Study (3 years after last patient will be enrolled)
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Data on management practices compared to existing guidelines.
Prazo: End of Study (3 years after last patient will be enrolled)
|
Compare disease-specific management practices with existing guidelines. |
End of Study (3 years after last patient will be enrolled)
|
|
Data on center-specific practices on outcomes.
Prazo: End of Study (3 years after last patient will be enrolled)
|
Determine the influence of center-specific practices on patient outcomes. |
End of Study (3 years after last patient will be enrolled)
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Scott Palmer, MD, Duke Clinical Research Institute, Duke University
Publicações e links úteis
Publicações Gerais
- Swaminathan AC, Hellkamp AS, Neely ML, Bender S, Paoletti L, White ES, Palmer SM, Whelan TPM, Dilling DF; Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry investigators. Disparities in Lung Transplant among Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the IPF-PRO Registry. Ann Am Thorac Soc. 2022 Jun;19(6):981-990. doi: 10.1513/AnnalsATS.202105-589OC.
- Kim HJ, Snyder LD, Neely ML, Hellkamp AS, Hotchkin DL, Morrison LD, Bender S, Leonard TB, Culver DA; IPF-PRO Registry investigators. Clinical Outcomes of Patients with Combined Idiopathic Pulmonary Fibrosis and Emphysema in the IPF-PRO Registry. Lung. 2022 Feb;200(1):21-29. doi: 10.1007/s00408-021-00506-x. Epub 2022 Jan 7.
- de Andrade JA, Kulkarni T, Neely ML, Hellkamp AS, Case AH, Culver DA, Guntupalli K, Bender S, Conoscenti CS, Snyder LD; IPF-PRO Registry Investigators. Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Respir Res. 2022 Jan 7;23(1):3. doi: 10.1186/s12931-021-01921-7.
- Kim HJ, Snyder LD, Adegunsoye A, Neely ML, Bender S, White ES, Conoscenti CS, Strek ME; IPF-PRO Registry Investigators. Hospitalizations in patients with idiopathic pulmonary fibrosis. Respir Res. 2021 Sep 30;22(1):257. doi: 10.1186/s12931-021-01851-4.
- Salisbury ML, Conoscenti CS, Culver DA, Yow E, Neely ML, Bender S, Hartmann N, Palmer SM, Leonard TB; IPF-PRO Registry principal investigators as follows. Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry. Ann Am Thorac Soc. 2020 Nov;17(11):1413-1423. doi: 10.1513/AnnalsATS.201912-880OC.
- Fan Y, Bender SD, Conoscenti CS, Davidson-Ray L, Cowper PA, Palmer SM, de Andrade JA; IPF-PRO Registry Investigators. Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry. Chest. 2020 Jun;157(6):1522-1530. doi: 10.1016/j.chest.2019.12.041. Epub 2020 Jan 29.
- O'Brien EC, Hellkamp AS, Neely ML, Swaminathan A, Bender S, Snyder LD, Culver DA, Conoscenti CS, Todd JL, Palmer SM, Leonard TB; IPF-PRO Registry investigators. Disease Severity and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis: A Cross-Sectional Analysis of the IPF-PRO Registry. Chest. 2020 May;157(5):1188-1198. doi: 10.1016/j.chest.2019.11.042. Epub 2020 Jan 15.
- Todd JL, Neely ML, Overton R, Durham K, Gulati M, Huang H, Roman J, Newby LK, Flaherty KR, Vinisko R, Liu Y, Roy J, Schmid R, Strobel B, Hesslinger C, Leonard TB, Noth I, Belperio JA, Palmer SM; IPF-PRO Registry investigators. Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry. Respir Res. 2019 Oct 22;20(1):227. doi: 10.1186/s12931-019-1190-z.
- Snyder L, Neely ML, Hellkamp AS, O'Brien E, de Andrade J, Conoscenti CS, Leonard T, Bender S, Gulati M, Culver DA, Kaner RJ, Palmer S, Kim HJ; IPF-PRO Registry investigators. Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry. Respir Res. 2019 May 30;20(1):105. doi: 10.1186/s12931-019-1043-9.
- O'Brien EC, Durheim MT, Gamerman V, Garfinkel S, Anstrom KJ, Palmer SM, Conoscenti CS. Rationale for and design of the Idiopathic Pulmonary Fibrosis-PRospective Outcomes (IPF-PRO) registry. BMJ Open Respir Res. 2016 Jan 11;3(1):e000108. doi: 10.1136/bmjresp-2015-000108. eCollection 2016.
- Swaminathan AC, Weber JM, Todd JL, Palmer SM, Neely ML, Whelan TP, Kim GHJ, Leonard TB, Goldin J. Extent of lung fibrosis is of greater prognostic importance than HRCT pattern in patients with progressive pulmonary fibrosis: data from the ILD-PRO registry. Respir Res. 2025 Feb 28;26(1):73. doi: 10.1186/s12931-025-03136-6.
- Oldham JM, Neely ML, Wojdyla DM, Gulati M, Li P, Patel DC, Palmer SM, Todd JL; IPF-PRO Registry Investigators. Changes in Lung Function and Mortality Risk in Patients With Idiopathic Pulmonary Fibrosis. Chest. 2025 Aug;168(2):415-422. doi: 10.1016/j.chest.2025.02.018. Epub 2025 Feb 26.
- Sack C, Wojdyla DM, MacMurdo MG, Gassett A, Kaufman JD, Raghu G, Redlich CA, Li P, Olson AL, Leonard TB, Todd JL, Neely ML, Snyder LD, Gulati M; IPF-PRO Registry investigators. Long-Term Air Pollution Exposure and Severity of Idiopathic Pulmonary Fibrosis: Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry. Ann Am Thorac Soc. 2025 Mar;22(3):378-386. doi: 10.1513/AnnalsATS.202404-382OC.
- Wang L, Wu P, Liu Y, Patel DC, Leonard TB, Zhao H. Clustering-aided prediction of outcomes in patients with idiopathic pulmonary fibrosis. Respir Res. 2024 Oct 23;25(1):383. doi: 10.1186/s12931-024-03015-6.
- Lobo LJ, Liu Y, Li P, Ramaswamy M, Swaminathan AC, Veeraraghavan S, Fan Y, Neely ML, Palmer SM, Olson AL; ILD-PRO Registry investigatorsdagger. Design and baseline characteristics of the ILD-PRO registry in patients with progressive pulmonary fibrosis. BMC Pulm Med. 2024 Sep 27;24(1):468. doi: 10.1186/s12890-024-03247-8.
- Summer R, Todd JL, Neely ML, Lobo LJ, Namen A, Newby LK, Shafazand S, Suliman S, Hesslinger C, Keller S, Leonard TB, Palmer SM, Ilkayeva O, Muehlbauer MJ, Newgard CB, Roman J. Circulating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Respir Res. 2024 Jan 25;25(1):58. doi: 10.1186/s12931-023-02644-7.
- Neely ML, Hellkamp AS, Bender S, Todd JL, Liesching T, Luckhardt TR, Oldham JM, Raj R, White ES, Palmer SM. Lung function trajectories in patients with idiopathic pulmonary fibrosis. Respir Res. 2023 Aug 24;24(1):209. doi: 10.1186/s12931-023-02503-5.
- Ruan P, Todd JL, Zhao H, Liu Y, Vinisko R, Soellner JF, Schmid R, Kaner RJ, Luckhardt TR, Neely ML, Noth I, Porteous M, Raj R, Safdar Z, Strek ME, Hesslinger C, Palmer SM, Leonard TB, Salisbury ML. Integrative multi-omics analysis reveals novel idiopathic pulmonary fibrosis endotypes associated with disease progression. Respir Res. 2023 May 31;24(1):141. doi: 10.1186/s12931-023-02435-0.
- Menon AA, Gansen B, Mulder H, Neely ML, Papavasileiou P, Salisbury ML, Southern BD, Hesslinger C, Leonard TB, Meissner F, Todd JL. Mass spectrometry-based peripheral blood proteomics for biomarker discovery in idiopathic pulmonary fibrosis. Respir Res. 2025 Oct 22;26(1):294. doi: 10.1186/s12931-025-03377-5.
- Shetty S, Swaminathan AC, Li P, Neely ML, Olson AL, Snyder LD; ILD-PRO Registry investigators. Workplace Productivity Loss in Patients with Progressive Pulmonary Fibrosis: Data from the ILD-PRO Registry. Lung. 2026 May 27;204(1):32. doi: 10.1007/s00408-026-00895-x.
- Swaminathan AC, Mulder H, Neely ML, Schmid R, Belperio JA, Patel NM, Palmer SM, Todd JL. Expression of complement pathway genes is associated with progression of idiopathic pulmonary fibrosis. Respir Res. 2026 Mar 25;27(1):196. doi: 10.1186/s12931-026-03641-2.
- Neely ML, Todd JL, Snyder LD, Li P, Olson AL; IPF-PRO Registry Investigators *. Trajectories of Health-Related Quality of Life in Patients With Idiopathic Pulmonary Fibrosis. CHEST Pulm. 2024 Dec 27;3(4):100133. doi: 10.1016/j.chpulm.2024.100133. eCollection 2025 Dec.
- MacMurdo MG, Wojdyla DM, Gassett A, Kaufman JD, Raghu G, Redlich CA, Patel DC, Neely ML, Snyder LD, Gulati M, Sack C; IPF-PRO Registry investigators. Short-term air pollution exposure and hospitalizations in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Ann Am Thorac Soc. 2026 Sep 12:aaoag285. doi: 10.1093/annalsats/aaoag285. Online ahead of print.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimado)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- Pro00046131
- 1199.174 (Outro identificador: DCRI)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .